Anixa Biosciences, Inc. has announced in a press release that it, in collaboration with The Cleveland Clinic Foundation, presented updated positive data for a Phase 1 study of its breast cancer vaccine. The announcement followed a presentation by Dr. Emily Rhoades from the Cleveland Clinic. The company cautions that statements not based on historical facts, which may include expectations for future events and results, are forward-looking and subject to various risks and uncertainties.